We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
BioForm Medical Dec. 27 announced that the FDA approved Radiesse, the next-generation cosmetic dermal filler, for the long-lasting correction of moderate to severe facial wrinkles and folds such as nasolabial folds.
Dr. Reddy's Laboratories announced Dec. 27, that the FDA has granted final approval for the company's abbreviated new drug application (ANDA) for ondansetron hydrochloride tablets, 4 mg, 8 mg, 16 mg and 24 mg.
The Court of Appeals for the Federal Circuit in Washington, D.C., Dec. 26 affirmed the U.S. District Court's decision that upheld Eli Lilly and Company's Zyprexa patent expiring in 2011.
Hospira Dec. 26 announced the launch of ondansetron injection. The medication is the generic version of GlaxoSmithKline's Zofran, which posted 2005 U.S. sales of more than $600 million.
Takara Bio has entered into a license and material transfer agreement with the Peter MacCallum Cancer Centre in Melbourne, Australia to supply Takara Bio's RetroNectin for use in a Phase I clinical trial of multiple myeloma (MM).
Exelixis Dec. 22 announced the initiation of a Phase II clinical trial of XL880 in patients with gastric cancer. As previously announced, a Phase II trial of XL880 in patients with papillary renal cell carcinoma was initiated in June 2006.
Replidyne reported Dec. 26 that the current Phase III clinical trial comparing faropenem medoxomil to placebo and Ketek in patients being treated for acute exacerbation of chronic bronchitis (AECB) is being temporarily stopped to consider the exclusion of the Ketek arm in the study.